Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. Meeting Abstract

Industry Collaboration

cited authors

  • Halmos, B., Fu, P., Pennell, N. A., Otterson, G. A., Mekhail, T., Snell, M. R., Kuebler, J. P., Gadgeel, S. M., Conrad, A., Stefanski, A. T., Dowlati, A.

authors

Publication Date

  • May 20, 2011

webpage

published in

category

volume

  • 29

issue

  • 15

WoS Citations

  • 0

WoS References

  • 0